Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"We are determining now if we want to start the European process with a partner, or file first then partner. :
I like that they are determining that now.
Here is my routine. I take my first 2 Vascepa with my first meal of the day. The time of the first meal varies but that way I always take it with food. I also take a CoQ10 during the first meal.
With my second meal of the day I think my 3rd and 4th Vascepa.
At bedtime I take my statin as directed.
I take the CoQ10 at the first meal because if the statin is depleting the CoQ10 in my system then I replenish it at the first meal so I have it throughout the day.
North, momentum group is back this morning, I think they will be disappointed.
Dr Oz is just enough of a nut to believe the MO BS.
TTE, Try to be nice. It is getting to be that time of year. He knows if you are bad or good so be good for goodness sake.
I think 18 is a pretty good price for the secondary. If it would have occurred immediately following the news I think it would have been lower than 13. The stock fell to 13.56 without the secondary because of the mineral oil FUD. Because the mineral oil issue was taken care of prior to the secondary, I think we ended up with many less shares outstanding and a much better path forward from here. I think he is doing fine and price will improve from here.
Here is how you get to 18.00.
After giving effect to the sale of 11,111,112 ADSs in this offering at the assumed public offering price of $18.00 per ADS, after deducting the underwriting discounts and commissions and offering expenses payable by us, our as adjusted net tangible book value as of September 30, 2018 would have been approximately $134.4 million, or $0.42 per ADS. This represents an immediate increase in net tangible book value of $0.61 per ADS to existing shareholders and immediate dilution in net tangible book value of $17.58 per ADS to investors purchasing our ADSs in this offering. The following table illustrates this dilution on a per ADS basis:
Assumed public offering price per ADS $ 18.00
Net tangible book value per ADS as of September 30, 2018 $ (0.19 )
Increase per ADS attributable to investors in this offering 0.61
As adjusted net tangible book value per ADS after this offering $ 0.42
Dilution per ADS to investors in this offering $ 17.58
I have also been saying $18. Some people either need proof or perhaps they have a different agenda. Either way, there it is.
Thanks should go to Msk13 on StockTwits for providing proof.
Proof it is priced from StockTwits poster.
https://charts.stocktwits.com/production/original_146422676.jpeg
It takes three days for shares to settle. AMRN PR stated the shares would settle on 11/29, which is tomorrow. The shares were already bought. Everything I have seen says 18. If it was lower or higher someone would be publishing it.
It can be used without payment. Less features but still pretty good. Unlimited post.
There is one approval process in Europe but the marketing approvals need to occur in each country. Language, packaging and negotiation for pricing occurs at the country level. It is pretty onerous. I don't think a small company like Amarin would want to go it alone in Europe.
Short interest update $AMRN
Settlement Date Short Interest Avg Daily Share Volume Days To Cover
11/15/2018 11,354,568 17,939,623 1.000000
10/31/2018 17,500,650 10,687,612 1.637471
10/15/2018 13,052,628 26,912,387 1.000000
9/28/2018 16,229,338 40,089,798 1.000000
9/14/2018 12,145,010 3,765,011 3.225757
8/31/2018 10,457,742 3,509,964 2.979444
8/15/2018 7,198,761 2,492,784 2.887840
I follow him on twitter and our stocks do cross paths occasionally. He is usually on the opposite side of the trade. I don't care for what he does. I think it boils down to keeping your enemies closer.
He often exaggerates.
The offering price was $18.
It happens all the time. It has nothing to do with CEO talk. A group of shorts get together and take the stock down as a group.
From Twitter, pre-market plan to take it to 16.80. It worked.
Nathan Michaud
?
Verified account
@InvestorsLive
45m45 minutes ago
More
$AMRN $CMCM $VCEL game plans pre market -- this is how we do it every morning in the chat room -- here is the game plan for $AMRN short trade to $16.80 wash out (pre market) and chart break down $CMCM short trade off open:
30 Million is short term debt that needs to be paid back in the next year.
As of Sept 30th 2018, 30 million of the debt was estimated to be short term. By paying off this debt and securing a line of credit or other debt, it would get rid of a huge overhang on the balance sheet and clean things up for the future.
The payout escalates as the net revenue escalates so current terms to me are not so favorable although I agree they were for years. As you are trying to ramp up production and hire sales reps you are paying out more of your margin. That is what I meant by more favorable debt. Something more long term at this point would be good.
Cash flow positive has nothing to do with debt or lack there of. Cash flow positive just means they are bringing in more money than they are paying out.
About 84 Million is what they owe and will finish off their obligation.
With 200M, they can pay off the royalty debt and replace it with much more favorable debt.
Is there any grounds for a new citizens petition to request approval of at least ANCHOR without a completely new sNDA? An interim step before the new sNDA is filed for cardiovascular benefit?
Back in July when Budoff did that call with Adam F. and stat news I thought for sure Amarin stock would go for a run higher. What was it he said, 85% chance of success. I thought for sure the stock would slowly move higher once this news was digested. I think sometimes the shorts are so good at making up fake news that they forget it is fake.
For me, so much negativity was circulating it was hard holding on especially as the stock price dropped lower those first days of September. I had convinced myself at first there was little downside because the company was cash flow positive and would survive this. As time went on, I had to rethink my position by saying that if I lost everything i had in AMRN I would survive.
I think a couple of funds had been given bad information near the end and they were selling off their positions. It may be the same information that they tried to give to you. Glad you held on, I would have been banging my head against a wall if I would have let it go. I am sure with all you had invested you felt the same way.
2019 Spring Lipid update. See attached, this meeting is not until February but notice the attention Reduce-It and Omega 3's will get.
Preston Mason PhD
Michael Miller MD &
Peter H. Jones MD.
https://www.lipid.org/springclu#agenda
Just for comparison you should post the changes in the Vascepa arm and let us know how mineral oil has impacted them.
I agree that we need to see some proof. I have followed every conversation that Dr. Bhatt has engaged in on twitter and every '$AMRN' conversation and I have seen zero evidence that Dr. Bhatt has blocked anyone.
I also did a search of the words Bhatt and Blocked and do not see where anyone has mentioned that Bhatt has blocked them.
Just an FYI, I don't think that posters who flat out lie should be posting on this message board or any others.
Your quote is regarding Lovaza when they were trying to see if there was a reaction. My Internal Medicine doc has my Vascepa written with food and my statin at bedtime. That's pretty typical.
"You guys" are not one person with one opinion. I'm not, nor have I ever been in favor of a combo pill.
You are wrong. People who are unhealthy are not going to lump their drugs together and take them at the wrong time of day. Most manufacturers of statins including Lipitor and Crestor recommend that they are taken at night, on the basis of physiological studies which show that most cholesterol is synthesized when dietary intake is at its lowest. Vascepa prescriptions read that they should be taken with meals, Crestor and Lipitor prescriptions read that they should not be taken at bedtime. They are not being consumed at the same time.
i can't believe I am going to post on a thread about M.O.
How exactly are you taking mineral oil with statins? Mineral oil would be taken like Vascepa with food. statins, at least the majority of them, are taken at bedtime. They are not even taken at the same time of day. Just one more argument why this is all ridiculous.
This is just an application. It has not been granted yet.
Thanks to John Cappello and others for engaging Dr. Deepak Bhatt in great twitter conversations.
Dr. Deepak L. Bhatt
?
@DLBHATTMD
10h10 hours ago
More
Replying to @JrwilliWilliams @JohnCappello @DrDerekConnolly
Given how well icosapent ethyl performed in patients with diabetes, metabolic syndrome would be an appealing population for a next trial. Not sure a head to head trial would be feasible given current pricing of PCSK9 inhibitors though.
0 replies 0 retweets 4 likes
Reply Retweet Liked 4 Direct message
Dr. Deepak L. Bhatt
?
@DLBHATTMD
14h14 hours ago
More
Replying to @ra_fun @DrDerekConnolly
I view statins (LDL reduction) and icosapent ethyl (multiple mechanisms of benefit) as complementary approaches. However, if a patient cannot take statins due to side effects, I would not deny them icosapent ethyl, even though we did not study that. A combo pill seems brilliant.
0 replies 6 retweets 30 likes
Reply Retweet 6 Liked 30 Direct message
Dr. Deepak L. Bhatt
?
@DLBHATTMD
14h14 hours ago
More
Replying to @JohnCappello @DrDerekConnolly
While icosapent ethyl is a prescription drug and a highly purified ethyl ester of EPA, it is ultimately derived from nature. As such, I believe it has multiple therapeutic effects. Probably a Nobel prize in there for a basic scientist who can unravel exactly via what mechanisms.
1 reply 1 retweet 12 likes
Reply 1 Retweet 1 Liked 12 Direct message
When statins came out, cardiologist and cardiovascular surgeons lost business. Hospitals that did very lucrative Open Heart Surgeries lost business. Statins can and are prescribed by primary care/ internal medicine. Same will be true of Vascepa. You will not need a cardiologist or a cardiovascular surgeon or if you did it will not be until later in life. You are likely to end up dying from something else.
Statins turned the cardiovascular world on its end. Vascepa is going to flip it over again. The industry that should be thrilled by this drug, if they were really interested in helping patients, is going to resist it because it will ultimately harm their business.
Dr. Nissen, Matthew H., Adam F. have one thing in common. They try and pick apart the drugs. They try to create controversy. They try to bring down the drug. A good drug, which we have, always wins in the end.
Bhatt did discuss the fact that the logarithmic inflammation numbers did not show issues and that those with high ldl did nor fair worse in the placebo. If you were traveling that day you probably missed some of the detail that was being produced.
Based on what IR has said, Amarin management is preparing to continue to respond. They have something up their sleeves or they would not have responded to emails as they have.
These results are so phenomenal that it is going to take some time for people to believe. We know it is right in front of them because we have been following every Amarin paper and poster for years. Skeptics are having to point fingers because they truly can't comprehend what they are looking at. The drug is a game changer. You and I both know that.
In all due respect, instead of spending your time bashing management why don't you spend time knocking down those who are unwilling for whatever reason to understand how good this data is.
"He had the SEC plan in place." I was referring to BB selling all of his shares not JT.